Trial reportDigestive diseases and sciences2001
Cyclosporin A is a promising alternative to corticosteroids in autoimmune hepatitis.
Trial report in Digestive diseases and sciences, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- KASL clinical practice guidelines for management of autoimmune hepatitis 2022.Clinical and molecular hepatology · 2023Guideline
- Autoimmune hepatitis: Standard treatment and systematic review of alternative treatments.World journal of gastroenterology · 2017Pooled it
- Autoimmune hepatitis: Towards a personalized treatment.World journal of hepatology · 2024Review
- Review
- Autoimmune Hepatitis and Fibrosis.Journal of clinical medicine · 2023Review
- Liver Disease and Sickle Cell Disease: Auto-Immune Hepatitis more than a Coincidence; A Systematic Review of the Literature.Mediterranean journal of hematology and infectious diseases · 2023Review
- Calcineurin Inhibitors in the Treatment of Adult Autoimmune Hepatitis: A Systematic Review.Journal of clinical and translational hepatology · 2022Article
- Autoimmmune hepatitis.Cellular & molecular immunology · 2022Review
- Profiling the patient with autoimmune hepatitis on calcineurin inhibitors: a real-world-experience.European journal of gastroenterology & hepatology · 2020Article
- Efficacy of rituximab in difficult-to-manage autoimmune hepatitis: Results from the International Autoimmune Hepatitis Group.JHEP reports : innovation in hepatology · 2019Article
- Autoimmune Hepatitis-Immunologically Triggered Liver Pathogenesis-Diagnostic and Therapeutic Strategies.Journal of immunology research · 2019Review
- Harmful Effects and Potential Benefits of Anti-Tumor Necrosis Factor (TNF)-α on the Liver.International journal of molecular sciences · 2018Review
- Immunosuppressive drugs affect interferon (IFN)-γ and programmed cell death 1 (PD-1) kinetics in patients with newly diagnosed autoimmune hepatitis.Clinical and experimental immunology · 2017Article
- The use of immunosuppression in autoimmune hepatitis: A current literature review.Clinical and molecular hepatology · 2017Review
- Refractory Autoimmune Hepatitis: Beyond Standard Therapy.Digestive diseases and sciences · 2016Article
- Auto immune hepatitis.World journal of gastroenterology · 2016Review
- Diagnosis and Management of Autoimmune Hepatitis: Current Status and Future Directions.Gut and liver · 2016Review
- Autoimmune hepatitis.Frontiers of medicine · 2015Review
- Role of mycophenolate mofetil for the treatment of autoimmune hepatitis-an observational study.Journal of clinical and experimental hepatology · 2014Article
- Management of autoimmune hepatitis: Focus on pharmacologic treatments beyond corticosteroids.World journal of hepatology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Autoimmune hepatitis (AIH), a chronic T-cell-mediated liver injury, is treated with corticosteroids with or without Azathioprine. Corticosteroids are not universally effective and have serious side effects. Cyclosporin A was effective in refractory cases. To assess efficacy and safety of Cyclosporin A (Neoral) in induction of remission in AIH patients this study was performed. Nineteen consenting AIH patients (nine treatment-naive) were treated with cyclosporin A in an open label trial and followed for 26 weeks. Liver biopsy was done and hepatitis activity index (HAI) determined at the beginning and end of treatment. Four patients did not complete the study for various reasons. Mean AST and ALT levels decreased from 948.7 +/- 103.5 and 454.8 +/- 354 to 100.6 +/- 111.8 and 78.5 +/- 40.3 (P < 0.03, P < 0.001) respectively. HAI decreased from 15.2 +/- 3.16 to 7.14 +/- 4.01 (P < 0.005). Serum creatinine did not change significantly. In conclusion, low-dose cyclosporin A appears to be safe and effective even in treatment-naive autoimmune hepatitis patients. Randomized controlled trials are warranted.
Indexed as
Identifiers
11414311What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.